The Food and Drug Administration based its approval of prasugrel largely on a 13,608-patient, multicenter clinical trial that compared it with the approved dose of clopidogrel for acute coronary ...

It's not revolutionary to suggest that the blockbuster drug model is ... Medco will then compare Plavix's efficacy in 14,000 of those selected patients to Effient in 14,000 other Medco members to ...

Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world’s second-best selling drug, with Effient, a potential blockbuster drug sold by Indianapolis-based Eli ...

Eli Lilly said this morning that it's submitted its experimental anti-clotting drug to the FDA for approval. The company added that the drug, known generically as prasugrel, would be sold under ...

Now, analysts say they're no longer expecting the drug to be a blockbuster. "Even if the company isn't ready to give up on Effient, we are," a Goldman Sachs analyst writes to clients (as quoted by ...